Stenger Rachel M, Poelen Martien C M, Moret Ed E, Kuipers Betsy, Bruijns Sven C M, Hoogerhout Peter, Hijnen Marcel, King Audrey J, Mooi Frits R, Boog Claire J P, van Els Cécile A C M
Laboratory of Vaccine Research, Netherlands Vaccine Institute, Bilthoven.
Infect Immun. 2009 Feb;77(2):896-903. doi: 10.1128/IAI.00769-08. Epub 2008 Nov 17.
P.69 pertactin (P.69 Prn), an adhesion molecule from the causative agent of pertussis, Bordetella pertussis, is present in cellular and most acellular vaccines that are currently used worldwide. Although both humoral immunity and cellular immunity directed against P.69 Prn have been implicated in protective immune mechanisms, the identities of CD4(+) T-cell epitopes on the P.69 Prn protein remain unknown. Here, a single I-A(d)-restricted B. pertussis conserved CD4(+) T-cell epitope at the N terminus of P.69 Prn was identified by using a BALB/c T-cell hybridoma. The epitope appeared immunodominant among four other minor strain-conserved P.69 Prn epitopes recognized after vaccination and B. pertussis infection, and it was capable of evoking a Th1/Th17-type cytokine response. B. pertussis P.69 Prn immune splenocytes did not cross-react with natural variants of the epitope as present in Bordetella parapertussis and Bordetella bronchiseptica. Finally, it was found that the immunodominant P.69 Prn epitope is broadly recognized in the human population by CD4(+) T cells in an HLA-DQ-restricted manner. During B. pertussis infection, the epitope was associated with a Th1-type CD4(+) T-cell response. Hence, this novel P.69 Prn epitope is involved in CD4(+) T-cell immunity after B. pertussis vaccination and infection in mice and, more importantly, in humans. Thus, it may provide a useful tool for the evaluation of the type, magnitude, and maintenance of B. pertussis-specific CD4(+) T-cell mechanisms in preclinical and clinical vaccine studies.
百日咳杆菌黏附素(P.69 Prn)是百日咳病原体百日咳博德特氏菌的一种黏附分子,存在于目前全球使用的细胞疫苗和大多数无细胞疫苗中。尽管针对P.69 Prn的体液免疫和细胞免疫均参与了保护性免疫机制,但P.69 Prn蛋白上CD4(+) T细胞表位的具体情况仍不清楚。在此,通过使用BALB/c T细胞杂交瘤,在P.69 Prn的N端鉴定出一个单一的I-A(d)限制性百日咳博德特氏菌保守CD4(+) T细胞表位。该表位在接种疫苗和百日咳博德特氏菌感染后识别出的其他四个次要菌株保守P.69 Prn表位中显得具有免疫优势,并且能够引发Th1/Th17型细胞因子反应。百日咳博德特氏菌P.69 Prn免疫脾细胞与副百日咳博德特氏菌和支气管败血博德特氏菌中存在的该表位天然变体无交叉反应。最后发现,免疫优势P.69 Prn表位在人群中被CD4(+) T细胞以HLA-DQ限制性方式广泛识别。在百日咳博德特氏菌感染期间,该表位与Th1型CD4(+) T细胞反应相关。因此,这个新的P.69 Prn表位参与了小鼠百日咳博德特氏菌疫苗接种和感染后的CD4(+) T细胞免疫,更重要的是,参与了人类的此类免疫。因此,它可能为临床前和临床疫苗研究中评估百日咳博德特氏菌特异性CD4(+) T细胞机制的类型、强度和维持情况提供一个有用的工具。